


## PRODUCT: **BS-181 dihydrochloride**

**ALTERNATE NAME:** *N*<sup>6</sup>-(6-Aminoethyl)-3-(1-methylethyl)-*N*<sup>7</sup>-(phenylmethyl)pyrazolo[1,5-a]pyrimidine-5,7-diamine dihydrochloride

**CATALOG #:** B2180-5,25

**AMOUNT:** 5 mg, 25 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>22</sub>H<sub>32</sub>N<sub>6</sub>·2HCl

**MOLECULAR WEIGHT:** 453.45

**CAS NUMBER:** 1092443-52-1 (free base)

**APPEARANCE:** White solid

**SOLUBILITY:** DMSO (>40 mg/ml) or H<sub>2</sub>O (>40 mg/ml)

**PURITY:** ≥97% by HPLC

**STORAGE:** Store at -20 °C. Protect from light and moisture

**DESCRIPTION:** BS-181 dihydrochloride is a potent and selective CDK7 inhibitor (IC<sub>50</sub> = 21 nM). It displays >40-fold selectivity for CDK7 over others CDKs. Promotes cell cycle arrest and apoptosis in a range of cancer cells *in vitro* and inhibits MCF-7 tumor xenograft growth in mice.

**REFERENCES:** Ali, S., *et al.* (2009). *Cancer Res.* **69**, 6208-6215

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**RELATED PRODUCTS:**

- AT-9823 (Cat. No. 2432-5, 25)
- Aurora Kinase B Inhibitor (Cat. No. 1583-5, 25)
- AZD1480 (Cat. No. 2315-1, 5)
- CCT-129202 (Cat. No. B1934-5,25)
- CCT-137690 (Cat. No. B1935-5,25)
- CP-690550 (Cat. No. 1622-5, 25)
- CYC-116 (Cat. No. B1936-5,25)
- Danusertib (Cat. No. B1937-5,25)
- ENMD-2076 (Cat. No. B1938-5,25)
- Lestaurtinib (Cat. No. 1805-500, 1000)
- MLN8237 (Cat. No. 2718-5,25)
- LLL12 (Cat. No. 1792-5, 25)
- MS-1020 (Cat. No. 1911-1)
- PF-03814735 (Cat. No. B1257-1,5)
- Reversine (Cat. No. 1851-1, 5)
- Ruxolitinib, free base (Cat. No. 2139-5, 25)
- Tozasertib (Cat. No. 1595-25, 100)
- EZSolution™ Tozasertib (Cat. No. 1803-TC-S 7010 (Cat. No. B1203-5,25)
- TG101348 (Cat. No. 2314-1, 5)
- Tyrphostin AG 490 (Cat. No. 1570-5)
- WHI-P131 (Cat. No. 1853-5, 25)
- WP1066 (Cat. No. 1809-5, 25)

**USAGE:** **FOR RESEARCH USE ONLY! Not to be used in humans**